18 Results for "

FGFR1-4

" in MedChemExpress (MCE) Product Catalog:
Products (18)

18 Results for "FGFR1-4" in MCE Product Catalog:

  • Targets Recommended:
101
101 Publications Verification
Art. -Nr.: HY-10981
CAS. Nr.: 417716-92-8
Reinheit:  99.75%
Synonyms: E7080
Target:  

VEGFR FGFR PDGFR c-Kit RET

Forschungsgebiete:  

Cancer

Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
loading...
    loading...
101
101 Publications Verification
Art. -Nr.: HY-10981A
CAS. Nr.: 857890-39-2
Reinheit:  99.86%
Synonyms: E7080 mesylate
Target:  

VEGFR FGFR PDGFR RET c-Kit

Forschungsgebiete:  

Cancer

Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
loading...
    loading...
8
8 Cited Publications
Art. -Nr.: HY-100818
CAS. Nr.: 1448169-71-8
Reinheit:  99.65%
Synonyms: TAS-120
Target:  

FGFR

Forschungsgebiete:  

Cancer

Futibatinib (TAS-120) is an orally bioavailable, highly selective, and irreversible FGFR inhibitor, with IC50s of 3.9, 1.3, 1.6, and 8.3 nM for FGFR 1-4, respectively. Futibatinib inhibits mutant and wild-type FGFR2 with similar IC50s (wild-type FGFR2=0.9 nM; V5651=1-3 nM; N550H=3.6 nM; E566G=2.4 nM) .
loading...
    loading...
1
1 Cited Publications
Art. -Nr.: HY-101768
CAS. Nr.: 1802929-43-6
Reinheit:  99.78%
Target:  

FGFR c-Fms

Forschungsgebiete:  

Cancer

PRN1371 is a highly selective and potent FGFR1-4 and CSF1R inhibitor with IC50s of 0.6, 1.3, 4.1, 19.3 and 8.1 nM for FGFR1, FGFR2, FGFR3, FGFR4 and CSF1R, respectively .
loading...
    loading...
Art. -Nr.: HY-10981S
CAS. Nr.: 2264050-65-7
Reinheit:  99.59%
Synonyms: E7080-d4
Lenvatinib-d4 is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
loading...
    loading...
Art. -Nr.: HY-156632
CAS. Nr.: 2750709-91-0
Reinheit:  99.53%
Synonyms: KIN-3248
Target:  

FGFR

Forschungsgebiete:  

Cancer

Resigratinib (KIN-3248) is an irreversible and orally active covalent inhibitor of FGFR1-4 that effectively inhibits wild-type and drug-resistant mutations (such as FGFR2 V565F, FGFR3 V555M). Resigratinib covalently binds to the Cys492 site of FGFR, blocks the FGFR signaling pathway, inhibits tumor cell proliferation and induces apoptosis. Resigratinib can be used for the study of FGFR2/3-driven solid tumors (such as cholangiocarcinoma and bladder cancer) .
loading...
    loading...
Art. -Nr.: HY-10981R
CAS. Nr.: 417716-92-8
Synonyms: E7080 (Standard)
Forschungsgebiete:  

Cancer

Lenvatinib (Standard) is the analytical standard of Lenvatinib. This product is intended for research and analytical applications. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
loading...
    loading...
Art. -Nr.: HY-100818R
CAS. Nr.: 1448169-71-8
Synonyms: TAS-120 (Standard)
Forschungsgebiete:  

Cancer

Futibatinib (Standard) is the analytical standard of Futibatinib. This product is intended for research and analytical applications. Futibatinib (TAS-120) is an orally bioavailable, highly selective, and irreversible FGFR inhibitor, with IC50s of 3.9, 1.3, 1.6, and 8.3 nM for FGFR 1-4, respectively. Futibatinib inhibits mutant and wild-type FGFR2 with similar IC50s (wild-type FGFR2=0.9 nM; V5651=1-3 nM; N550H=3.6 nM; E566G=2.4 nM) .
loading...
    loading...
Art. -Nr.: HY-133980A
Reinheit:  95.54%
Target:  

Drug Metabolite

Forschungsgebiete:  

Cancer

O-Demethyl Lenvatinib hydrochloride is a metabolite of Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET. Lenvatinib shows potent antitumor activities .
loading...
    loading...
Art. -Nr.: HY-133980
CAS. Nr.: 417717-04-5
Target:  

Drug Metabolite

Forschungsgebiete:  

Cancer

O-Demethyl Lenvatinib is a metabolite of Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
loading...
    loading...
Art. -Nr.: HY-10981S1
Synonyms: E7080-d5
Lenvatinib-d5 is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
loading...
    loading...
Art. -Nr.: HY-10981AR
CAS. Nr.: 857890-39-2
Synonyms: E7080 mesylate (Standard)
Forschungsgebiete:  

Cancer

Lenvatinib (mesylate) (Standard) is the analytical standard of Lenvatinib (mesylate). This product is intended for research and analytical applications. Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
loading...
    loading...
Art. -Nr.: HY-10981S2
Synonyms: E7080-15N,d4
Lenvatinib- 15N,d4 is 15N and deuterated labeled Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
loading...
    loading...
Art. -Nr.: HY-168653
Target:  

FGFR

Forschungsgebiete:  

Cancer

FGFR-IN-15 (compound 18i) is a pan-FGFR inhibitor with potently inhibitory activity against FGFR1-4. .
loading...
    loading...
Art. -Nr.: HY-170919
CAS. Nr.: 3025799-28-1
Target:  

FGFR

Forschungsgebiete:  

Cancer

FGFR2/3-IN-2 (compound 10) is an orally active FGFR2 and FGFR3 inhibitor. FGFR2/3-IN-2 inhibits FGFR2 and FGFR3 with IC50s of 3.7 nM and 31.2 nM (preincubation time 1 h), respectively. FGFR2/3-IN-2 spares FGFR1/4 and other kinases without causing diarrhea and serum phosphate elevation in vivo. FGFR2/3-IN-2 induces tumor stasis or regression in the SNU-16 gastric cancer model .
loading...
    loading...
Art. -Nr.: HY-172922
Target:  

FGFR

Forschungsgebiete:  

Cancer

Arg-IN-1 is a selective Arginine (Arg)-targeting covalent inhibitor with IC50s of 9.7 nM and 30.4 nM for FGFR2 and FGFR3,respectively. Arg-IN-1 has the potential to avoid FGFR1/4-targeted toxicity as well as conquer acquired on-target resistance, potential for FGFR-targeting cancer therapy .
loading...
    loading...
Art. -Nr.: HY-101768R
CAS. Nr.: 1802929-43-6
Forschungsgebiete:  

Cancer

PRN1371 (Standard) is the analytical standard of PRN1371 (HY-101768). This product is intended for research and analytical applications. PRN1371 is a highly selective and potent FGFR1-4 and CSF1R inhibitor with IC50s of 0.6, 1.3, 4.1, 19.3 and 8.1 nM for FGFR1, FGFR2, FGFR3, FGFR4 and CSF1R, respectively .
loading...
    loading...
Art. -Nr.: HY-184598
Forschungsgebiete:  

Cancer

CYB-5067 is a FGFR molecular glue degrader with a DC50 of 27 nM against FGFR2. CYB-5067 inhibits FGFR1, FGFR3, FGFR4 and downstream FGFR signaling pathways, induces antiproliferative activity in vitro, and exhibits sustained target protein inhibition in vivo without obvious hook effect. CYB-5067 shows significant tumor growth inhibitory activity in the ETV6-FGFR2 fusion Ba/F3 xenograft model. CYB-5067 can be used for the research of FGFR-driven cancers .
loading...
    loading...
  • 1